Stemrim Inc. (4599) Press Release
StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (SR-GT1) Aimed at Curative Treatment of DEB in,South Korea
Earlier from Stemrim
- [Delayed]Notice Regarding Recognition of Non-operating Income (Subsidy Income)
- StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
- StemRIM Announces Patent Registration (Russia) for Redasemtide, as a Therapeutic Indication for Fatty Liver and Non-alcoholic Steatohepatitis
- Non-consolidated Financial Results for the Nine Months Ended April 30, 2026 [Japanese GAAP]